These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 27213201)
1. [Direct Acting Antivirals for Treatment of Hepatitis C Infection in Patients with Advanced Liver Disease]. Chung WJ Korean J Gastroenterol; 2016 Jan; 67(1):58-60. PubMed ID: 27213201 [No Abstract] [Full Text] [Related]
2. [Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection]. Yang J; Rao HY Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):175-178. PubMed ID: 29804389 [TBL] [Abstract][Full Text] [Related]
3. A review of direct-acting antivirals for the treatment of hepatitis C in patients with advanced chronic kidney disease. Maruyama A; Partovi N; Yoshida EM; Erb SR; Azalgara VM; Hussaini T Nephrol Dial Transplant; 2017 Jan; 32(1):35-41. PubMed ID: 26481484 [TBL] [Abstract][Full Text] [Related]
4. Efficacy of Direct-Acting Antivirals Compared with Older Agents for Hepatitis C. Ta K; Zehtabchi S Am Fam Physician; 2017 Jun; 95(11):Online. PubMed ID: 28671433 [No Abstract] [Full Text] [Related]
5. [Therapeutic update in hepatitis C]. Devesa MJ; Cuenca F; Izquierdo S; Sánchez-Pobre P; Ladero JM; López-Alonso G; Díaz-Rubio M; Rey E Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():48-51. PubMed ID: 26365735 [TBL] [Abstract][Full Text] [Related]
6. Caution with the use of the new direct acting antivirals in the hepatitis C virus related renal disease. Gomis A; Díaz M; de Lorenzo A; Ruiz-Roso G; Liaño F Nefrologia; 2016; 36(6):713-715. PubMed ID: 27575928 [No Abstract] [Full Text] [Related]
7. Treating hepatitis B virus/hepatitis C virus coinfected patients with direct-acting hepatitis C virus antivirals only is not safe. Ozaras R; Sunbul M; Parlak M; Bodur H; Leblebicioglu H Hepatology; 2016 Nov; 64(5):1825-1827. PubMed ID: 27043022 [No Abstract] [Full Text] [Related]
8. Managing hepatitis C virus-HIV liver transplant recipients with the new direct-acting antivirals: are we glimpsing a brilliant future behind our shoulders? Fagiuoli S; Puoti M; Rizzardini G AIDS; 2016 Jan; 30(2):323-5. PubMed ID: 26684824 [No Abstract] [Full Text] [Related]
9. Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up. Fabrizi F; Aghemo A; Lampertico P; Fraquelli M; Cresseri D; Moroni G; Passerini P; Donato FM; Messa P Int J Artif Organs; 2018 Jun; 41(6):306-318. PubMed ID: 29595085 [TBL] [Abstract][Full Text] [Related]
10. [Predictive factors of response to Direct Acting Antivirals therapy Drug resistance hepatitis C virus]. Suda G; Yamasaki K; Sakamoto N Nihon Rinsho; 2015 Dec; 73 Suppl 9():189-92. PubMed ID: 26845928 [No Abstract] [Full Text] [Related]
11. Pre- Versus Posttransplant Treatment of Hepatitis C Virus With Direct-Acting Antivirals in Liver Transplant Recipients: More Issues to be Solved. Abdelqader A; Kabacam G; Woreta TA; Hamilton JP; Luu H; Al Khalloufi K; Saberi B; Philosophe B; Cameron AM; Gurakar A Exp Clin Transplant; 2017 Feb; 15(Suppl 1):1-5. PubMed ID: 28260422 [TBL] [Abstract][Full Text] [Related]
12. Feasibility and acceptability of adherence support for direct acting antiviral therapy for hepatitis C in a low-threshold primary health-care opioid agonist treatment program. Chronister KJ; Lothian R; Gilliver R; Kearley J; Read P Drug Alcohol Rev; 2019 Feb; 38(2):185-189. PubMed ID: 30761640 [TBL] [Abstract][Full Text] [Related]
13. Successful treatment of hepatitis C virus infection with direct-acting antivirals during hematopoietic cell transplant. Cunningham HE; Shea TC; Grgic T; Lachiewicz AM Transpl Infect Dis; 2019 Jun; 21(3):e13091. PubMed ID: 30972834 [TBL] [Abstract][Full Text] [Related]
14. The oncogenic hepatitis C virus and direct-acting antivirals: economic implications for hepatocellular carcinoma in Medicaid beneficiaries with cirrhosis. Mantravadi S Am J Manag Care; 2017 Apr; 23(5 Spec No.):SP180-SP184. PubMed ID: 28665676 [No Abstract] [Full Text] [Related]
15. Hepatitis C virus infection in maintenance hemodialysis patients: recommendations for diagnostics and treatment. Dzekova-Vidimliski P; Sikole A Int J Artif Organs; 2017 Feb; 39(12):590-595. PubMed ID: 28165585 [TBL] [Abstract][Full Text] [Related]
16. Fibrosing Cholestatic Hepatitis C After Liver Transplantation: Therapeutic Options Before and After Introduction of Direct-Acting Antivirals: Our Experience and Literature Review. Tronina O; Ślubowska K; Mikołajczyk-Korniak N; Komuda-Leszek E; Wieczorek-Godlewska R; Łągiewska B; Pacholczyk M; Lisik W; Kosieradzki M; Durlik M Transplant Proc; 2017; 49(6):1409-1418. PubMed ID: 28736015 [TBL] [Abstract][Full Text] [Related]
17. Emerging issues on hepatitis C virus infection after the introduction of the Directly Acting Antivirals. Ippolito G; Antonelli G Clin Microbiol Infect; 2016 Oct; 22(10):824-825. PubMed ID: 27863749 [No Abstract] [Full Text] [Related]
18. Editorial commentary: Management of hepatitis C Virus in HIV-infected patients in the era of direct-acting antivirals. Zeremski M; Martinez AD; Talal AH Clin Infect Dis; 2014 Mar; 58(6):880-2. PubMed ID: 24336913 [No Abstract] [Full Text] [Related]
19. Management of hepatitis C patients with decompensated liver disease. Hsu CS; Kao JH Expert Rev Gastroenterol Hepatol; 2016 Jun; 10(6):679-88. PubMed ID: 26782619 [TBL] [Abstract][Full Text] [Related]
20. Role of Direct-Acting Antivirals in Hepatitis C Virus-Positive Castleman Disease. Tahir M; Charles L Am J Ther; 2018; 25(6):e733-e734. PubMed ID: 29557805 [No Abstract] [Full Text] [Related] [Next] [New Search]